As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond ...

GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...

A new study uncovers how widely used weight loss drugs like Ozempic impact various health conditions while posing notable ...

Oikos and its other popular brands are seeing a spike in demand as people taking the weight-loss medications turn to the portion-controlled snacks to meet their nutritional needs.

RELATED: Doctor Says Ozempic Raises Certain Health Risks by Up to 900%. Per the study, weight-loss drugs can lower the risk for 42 health conditions, while also raising someone’s risk of developing 19 ...